A detailed history of Provident Investment Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Provident Investment Management, Inc. holds 160,125 shares of VRTX stock, worth $75.1 Million. This represents 6.27% of its overall portfolio holdings.

Number of Shares
160,125
Previous 160,319 0.12%
Holding current value
$75.1 Million
Previous $65.2 Million 2.61%
% of portfolio
6.27%
Previous 6.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $79,091 - $86,539
-194 Reduced 0.12%
160,125 $66.9 Million
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $291,550 - $349,078
-850 Reduced 0.53%
160,319 $65.2 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $358,470 - $384,207
-1,060 Reduced 0.65%
161,169 $56 Million
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $256,252 - $286,806
-815 Reduced 0.5%
162,229 $57.1 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $656,243 - $748,622
2,317 Added 1.44%
163,044 $51.4 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $371,488 - $417,924
-1,300 Reduced 0.8%
160,727 $46.4 Million
Q3 2022

Nov 17, 2022

SELL
$273.83 - $305.53 $2.01 Million - $2.24 Million
-7,328 Reduced 4.33%
162,027 $46.9 Million
Q2 2022

Aug 11, 2022

SELL
$234.96 - $292.55 $4.22 Million - $5.25 Million
-17,959 Reduced 9.59%
169,355 $47.7 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $472,731 - $557,170
2,135 Added 1.15%
187,314 $48.9 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $320,919 - $405,114
1,813 Added 0.99%
185,179 $40.7 Million
Q3 2021

Nov 10, 2021

BUY
$181.39 - $202.99 $1.18 Million - $1.33 Million
6,531 Added 3.69%
183,366 $33.3 Million
Q2 2021

Aug 06, 2021

BUY
$187.49 - $221.1 $33.2 Million - $39.1 Million
176,835 New
176,835 $35.7 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Provident Investment Management, Inc. Portfolio

Follow Provident Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Provident Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Provident Investment Management, Inc. with notifications on news.